Pharmaceutical composition for treating endometritis
By designing and optimizing the antimicrobial peptide A24 and its combined use with ceftiofuro sodium, the problem of antibiotic resistance in endometritis was solved, and efficient inhibition of Staphylococcus aureus and effective treatment of endometritis was achieved. , demonstrates the potential of new green antibiotic alternatives.
Patent Information
- Application Number
- CN202411043820.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-12
AI Technical Summary
The existing antibiotics for endometritis are not effective in treating endometritis due to drug resistance problems, and a new, green, non-resistant antibiotic replacement product is urgently needed to solve endometritis caused by Staphylococcus aureus.
A method of using antimicrobial peptide A24 and its combined use with ceftiofur sodium was developed. The antimicrobial peptide A24 was designed through bioinformatics technology to improve its inhibitory effect on Staphylococcus aureus, and achieved high-density fermentation and purification technology. Yield expression, combined with bioinformatics, optimize amino acid sequence and buffer conditions to improve its safety and efficacy.
Antibacterial peptide A24 significantly inhibits drug-resistant Staphylococcus aureus and has a rapid bactericidal effect. It is better than vancomycin and ceftifurosodium, which can pass through the cell membrane to kill bacteria. The combination of ceftifurosodium significantly reduces the symptoms of endometriitis and Inflammatory factors, protect uterine tissue, show better therapeutic potential.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a drug combination for treating endometritis. Background Art
[0002] Endometritis is a common disease in humans and livestock, which seriously endangers human health and the production and fertility of livestock, and poses a huge challenge to human public health safety and the economic development of animal husbandry. Staphylococcus aureus is one of the main pathogens causing the disease. It can secrete a variety of virulence factors such as hemolytic toxins, exfoliants, leukocidins, enterotoxins, extracellular enzymes and surface protein adhesion factors in uterine epithelial cells, which have hemolytic and cell-killing effects (Eckert LO, 2014), causing local inflammation of the uterus. At present, the drugs used to treat endometritis are mainly antibiotics such as penicillin, cephalosporins and Chinese herbal medicine Gongyanqing, but due to the improper use of antibiotics, many bacteria have developed drug resistance, especially the emergence of multidrug resistance in Staphylococcus aureus (Cheung GYC, 2021), which poses a huge threat to humans. It is urgent to develop a new, green, and non-resistant antibiotic alternative product to solve this problem.
[0003] In the 1980s, Boman's team discovered and reported typical insect-derived antimicrobial peptides, called cecropins, which played a milestone in the development of antimicrobial peptides (Zasloff et al., 2002). Antimicrobial peptides are widely available and can be produced by animals, plants, and microorganisms such as bacteria and fungi. They have antimicrobial, immune regulation, and nutritional functions (Lazzaro BP, 2020). At the same time, their unique cationic and hydrophobic properties enable them to interact with bacterial cell membranes, enter bacteria, and interact with intracellular nucleic acids or proteases to affect transcription, translation, or metabolism, causing bacterial death, and are not prone to drug resistance. Researchers use their high antibacterial and nutritional value to use genetic engineering technology to achieve high-yield products in vitro, providing a solid foundation for drug research and development and feed additive development. Therefore, AMPs with good activity and the ability to achieve high-yield preparation in vitro are considered to be one of the most powerful candidates for future antimicrobial drugs (Ali Adem Bahar et al., 2013). Plectasin is a fungal defensin isolated from a saprophytic ascomycete on the surface of a Nordic pine forest. It has good activity against Gram-positive bacteria. It includes an inactive precursor peptide and a mature peptide composed of 40 amino acids with antibacterial activity. The mature peptide has a unique CS αβ secondary structure consisting of an N-terminal α-helix stabilized by three pairs of disulfide bonds and a C-terminal β-folded structure, which forms a strong and close structure-activity relationship with its highly effective antibacterial activity. As early as 2005, Mygind et al. studied the inhibitory effect of Plectasin on more than 130 strains of Streptococcus pneumoniae from different sources and found that for penicillin-sensitive or -resistant strains, the minimum bactericidal concentration (MIC) was between 0.1-8 μg / mL, and the MIC 50 1 μg / mL (Mygind, Fischer et al., 2005). Plectasin, as an active antimicrobial peptide, has attracted extensive attention from researchers. In order to improve its stability and safety, a variety of derivative peptides have been designed. Among them, the antimicrobial peptide AP138 was obtained by Lociuro S in 2015 through computer mutation screening. It was verified by chemical synthesis that it has good antibacterial activity against Staphylococcus aureus and is a candidate drug for the post-antibiotic resistance era (Lociuro S, 2015). Later, GrooAC studied in 2018 that the MIC of AP138 after encapsulation was 0.125-4 μg / mL for some Staphylococcus aureus, and it can be used as a candidate drug for inhibiting diseases caused by Gram-positive bacteria Staphylococcus aureus (Groo AC, 2018). At the same time, the use of a single antimicrobial peptide drug in vivo may be purely due to the short efficacy period and poor effect. Therefore, on this basis, the combination of antibiotics to synergistically exert the efficacy can not only reduce the concentration of antibiotics used to alleviate the problem of drug resistance, but also significantly improve the efficacy. The concept of antimicrobial peptides and their combination with antibiotics provides a new idea for the treatment of endometritis. Summary of the invention
[0004] The purpose of the present invention is to provide a novel antimicrobial peptide A24 and its combined use with ceftiofur sodium.
[0005] Another object of the present invention is to provide a pharmaceutical combination for treating endometritis.
[0006] The present invention uses 5 L of Pichia pastoris for high-density fermentation for 120 h to achieve high-yield expression of antimicrobial peptide AP138 (up to 3.1 g / L), and verifies that it has a certain bactericidal effect on Staphylococcus aureus, Streptococcus and Staphylococcus epidermidis, and has low hemolytic activity. In order to further improve the safety of AP138 antibacterial active agent, the present invention uses bioinformatics technology to design a variety of antimicrobial peptide AP138 derivative peptides, among which the activity of antimicrobial peptide A24 against pathogenic Gram-positive bacteria is increased by 4 times, and it can be expressed in high yield in vitro (up to 3.9 g / L), and on the basis of laboratory preliminary cation exchange column purification, the concentration of buffer A and B is optimized (from 20 mM to 50 mM) and the pH of buffer A and B is optimized (6.7 to 7.0), and a pure product is obtained. At present, there is no report on the in vitro efficacy of antimicrobial peptide A24 and its combination with ceftriaxone sodium against drug-resistant Staphylococcus aureus and the therapeutic effect of infection-induced endometritis.
[0007] In order to achieve the purpose of the present invention, in a first aspect, the present invention provides an antimicrobial peptide A24, which comprises or consists of the following amino acid sequence: i) the amino acid sequence shown in SEQ ID NO: 2; or
[0008] ii) An amino acid sequence obtained by connecting a tag to the N-terminus and / or C-terminus of i).
[0009] In a second aspect, the present invention provides a nucleic acid molecule encoding antimicrobial peptide A24.
[0010] In a third aspect, the present invention provides biological materials containing the nucleic acid molecule, wherein the biological materials include but are not limited to recombinant DNA, expression cassettes, transposons, plasmid vectors, viral vectors, engineered bacteria or transgenic cell lines.
[0011] In a fourth aspect, the present invention provides use of antimicrobial peptide A24 in the preparation of antimicrobial drugs or compositions.
[0012] The bacteria are Gram-positive bacteria, preferably Staphylococcus aureus ( Staphylococcus aureus ) and drug-resistant Staphylococcus aureus.
[0013] In a fifth aspect, the present invention provides the use of antimicrobial peptide A24 in the preparation of a drug for preventing or treating endometritis; wherein the pathogenic bacteria of endometritis include Staphylococcus aureus and drug-resistant Staphylococcus aureus.
[0014] In a sixth aspect, the present invention provides a drug combination for treating endometritis, the drug combination comprising antimicrobial peptide A24 and the antibiotic ceftiofur sodium.
[0015] In the present invention, the antimicrobial peptide and ceftiofur sodium can be administered simultaneously or sequentially.
[0016] The antimicrobial peptide A24 and ceftiofur sodium were administered by intraperitoneal injection.
[0017] By means of the above technical solution, the present invention has at least the following advantages and beneficial effects: The present invention discovered for the first time that the antimicrobial peptide A24 has a significant inhibitory effect on drug-resistant Staphylococcus aureus and its biofilm. Experimental results show that the antimicrobial peptide A24 has a highly efficient and rapid bactericidal effect on Staphylococcus aureus, which is superior to vancomycin (Van) and ceftiofur sodium (Cef), and A24 is superior to the parent peptide AP138. At the same time, A24 can pass through the membrane of bovine uterine epithelial cells and kill intracellular Staphylococcus aureus, with an intracellular bactericidal rate of more than 90%. In in vitro tests, A24 and ceftiofur sodium have a combined bactericidal effect, and the low-dose combination can significantly inhibit the growth of Staphylococcus aureus. In experiments on mouse endometritis models, A24 and its combination with ceftiofur sodium can reduce the increase in white blood cells caused by bacteria; at the same time, it can also significantly reduce the bacterial load in the mouse uterus and the pro-inflammatory factor IL-6; and can protect tissues from damage. The above indicators show that the derivative peptide A24 is better than the parent peptide AP138, but lower than the combination group; therefore, the combination of antimicrobial peptide A24 and ceftiofur sodium has the potential to be developed into a new preparation for the treatment of endometritis caused by Staphylococcus aureus. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 The AP138 and A24 in the preferred embodiment of the present invention are effective against Staphylococcus aureus ( Staphylococcus aureus ATCC 43300) in vitro bactericidal kinetic curve.
[0019] Figure 2 The AP138 and A24 in the preferred embodiment of the present invention are effective against Staphylococcus aureus ( Staphylococcus aureus In vitro bactericidal kinetic curve of CVCC546).
[0020] Figure 3 The antimicrobial peptides AP138 and A24 in the preferred embodiment of the present invention are effective against Staphylococcus aureus ( Staphylococcus aureus ATCC 43300) post-antibiotic effect (PAE).
[0021] Figure 4The antimicrobial peptides AP138 and A24 in the preferred embodiment of the present invention are effective against Staphylococcus aureus ( Staphylococcus aureus CVCC546) post-antibiotic effect (PAE).
[0022] Figure 5 The stability of antimicrobial peptides AP138 and A24 in mouse serum in the preferred embodiment of the present invention.
[0023] Figure 6 The effect of antimicrobial peptide A24 on the cell membrane integrity of Staphylococcus aureus CVCC 546 in the preferred embodiment of the present invention
[0024] Figure 7 This is the observation of the entry of antimicrobial peptides AP138 and A24 into bovine uterine epithelial cells under a fluorescence microscope in a preferred embodiment of the present invention.
[0025] Figure 8 The killing effect of antimicrobial peptides AP138 and A24 on intracellular Staphylococcus aureus CVCC546 in the preferred embodiment of the present invention. .
[0026] Fig. 9 This is an in vivo acute toxicity test of the antimicrobial peptide A24 in a preferred embodiment of the present invention on mice injected intraperitoneally for 7 consecutive days.
[0027] Fig.10 This is a preferred example of the present invention in which the antimicrobial peptide A24 combined with ceftiofur sodium inhibits the growth of Staphylococcus aureus.
[0028] Fig.11 This is the effect of the antimicrobial peptide A24 and its combination with ceftiofur sodium on the inflammatory factor IL-6 after treatment of endometritis in mice in the preferred embodiment of the present invention.
[0029] Fig.12 This is the effect of the antimicrobial peptide A24 and its combination with ceftiofur sodium on the bacterial load in the uterine organs of mice after treatment of endometritis in the preferred embodiment of the present invention. .
[0030] Fig.13 This is the effect of the antimicrobial peptide A24 and its combination with ceftiofur sodium on the pathological sections of the tissues after treatment of endometritis in mice in the preferred embodiment of the present invention. DETAILED DESCRIPTION
[0031] The present invention explores the antibacterial method of Staphylococcus aureus, and accidentally finds that fungal defensin AP138 and its derivative peptide A24 have a good antibacterial effect on drug-resistant Staphylococcus aureus, and have a good synergistic effect with ceftiofur sodium.
[0032] The antimicrobial peptide AP138 (SEQ ID NO: 1) was analyzed by bioinformatics, and its amino acid sequence was mutated to obtain the derivative peptide A24 (SEQ ID NO: 2). A24 showed better antibacterial effect than the parent peptide. The antimicrobial peptide AP138 and its derivative peptide A24 have efficient in vitro bactericidal activity against multidrug-resistant Staphylococci, and show the characteristics of rapidity, long after-effect, low drug resistance and high safety. The bactericidal efficiency and antibiotic post-effect of the antimicrobial peptide A24 are significantly higher than those of vancomycin or ceftiofur sodium, and are better than those of the parent peptide AP138. At the same time, the antimicrobial peptide A24 and ceftiofur sodium have a combined effect to inhibit Staphylococcus aureus. The mechanism of action of the antimicrobial peptide A24 is consistent with that of AP138. It can destroy the integrity of the cell membrane to kill bacteria, and can also pass through mouse macrophages and uterine epithelial cells to kill intracellular bacteria. Antimicrobial peptides AP138 and A24 are safe for use in mice, do not damage cells, tissues and organs, and have a better therapeutic effect on endometritis infected with Staphylococcus aureus when combined with ceftiofur sodium. They can significantly relieve symptoms, regulate inflammatory factors, reduce the bacterial load of organs, and protect the uterus from organic damage, thereby achieving the purpose of treating endometritis. Antimicrobial peptide A24 and its combination with ceftiofur sodium have the potential for clinical application as a new therapeutic agent for endometritis caused by Staphylococcus aureus, especially the combination of antimicrobial peptide A24 and ceftiofur sodium shows a better therapeutic effect. In the present invention, the amino acid sequence of antimicrobial peptide AP138 is shown in SEQ ID NO: 1; the amino acid sequence of A24 is shown in SEQ ID NO: 2.
[0033] Based on the above findings, the present invention first provides the use of antimicrobial peptide A24 and its combination with ceftiofur sodium in the preparation of a drug for preventing or treating endometritis, wherein the pathogenic bacteria of endometritis include Staphylococcus aureus.
[0034] The Staphylococcus aureus may be a standard strain CVCC546, or a strain isolated from an animal with endometritis in a dairy cow.
[0035] The present invention also found that the antimicrobial peptide A24 can kill intracellular bacteria; AP138 and A24 may achieve the purpose of killing bacteria by destroying the cell membrane.
[0036] The intracellular cells mentioned above refer to mouse macrophages or bovine uterine epithelial cells.
[0037] The present invention also found that when using antimicrobial peptides and combined antibiotics to treat mouse endometritis models, at least the following effects are achieved: (1) Inhibit Staphylococcus aureus and its drug-resistant bacteria; (2) Increase the immune regulation level of mice and reduce the level of inflammatory factors; (3) Protect the mouse uterus from damage.
[0038] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.
[0039] Example 1 Determination of Minimum Inhibitory Concentration of Antimicrobial Peptide A24
[0040] The pathogens in this example are all from the China Veterinary Microbial Culture Collection (CVCC) or the American Type Culture Collection (ATCC), and the specific strains are shown in Table 1. The determination of the minimum inhibitory concentration (MIC) and the minimum bactericide concentration (MBC) of antimicrobial peptides was based on the method established by the Clinical and Laboratory Standards Institute (CLSI), with slight modifications according to actual conditions, as follows: a single colony of the test strain was picked up and placed in MHB medium, cultured overnight at 37°C 250 rpm until the logarithmic phase, and then prepared into 10 5 CFU / mL of bacterial solution, 90 μL was taken into a 96-well sterile cell culture plate. Then 10 μL of two-fold gradient dilution of antimicrobial peptide AP138 was added to the final concentration of 128, 64, 32, 16, 8, 4, 2, 1 and 0.5 μg / mL. The negative control group was PBS instead of the test bacterial solution of antimicrobial peptide, and the blank control group was sterile MH medium. Three parallel samples were used for each treatment. The culture plate was placed in a 37℃ constant temperature incubator for 16-18h until the negative control well showed obvious turbid bacterial solution visible to the naked eye. The lowest concentration that can completely inhibit bacterial growth is the MIC value of the antimicrobial peptide against the test strain (Zhang Y, 2014). The results are shown in Table 1. The MIC of antimicrobial peptide A24 against Staphylococcus aureus is 1-4μg / mL, which is 4 times higher than that of the parent peptide AP138.
[0041] Table 1 MICs of antimicrobial peptides AP138 and A24 against Gram-positive bacteria
[0042] The inhibitory effect of antimicrobial peptide A24 on 8 clinical isolates of Staphylococcus aureus was further investigated, and the minimum inhibitory concentration (MIC) of A24 was determined. The specific method was as described above. The results are shown in Table 2: Antimicrobial peptide A24 has good antibacterial activity against 8 isolated resistant S. aureus, with MIC values ranging from 1 to 4 µg / mL, which is significantly higher than the MIC of the parent peptide AP138 (4 to 8 µg / mL).
[0043] Table 2 MIC and MBC of antimicrobial peptide A24 against isolated resistant Staphylococcus aureus
[0044] Example 2 Determination of mutant prevention concentrations (MPC) of antimicrobial peptide A24 against Staphylococcus aureus CVCC546
[0045] Based on the MIC, the antimicrobial peptide solution was mixed with an equal amount of sterilized and cooled solid culture medium TSA and poured into the plate. The final drug concentration ranged from 1 × MIC to 64 × MIC. The concentration of Staphylococcus aureus in the logarithmic growth phase was controlled at 1 × 10 10 CFU / mL. 100 μL of bacterial solution was spread on the drug plate with the above multiple concentrations, and then cultured in a 37°C incubator. The lowest drug concentration at which no colony growth occurred for 72 h was MPC. The results are shown in Table 3. The ratio of MPC to MIC (Selection index) SI reflects the ability of antimicrobial drugs to limit the selection of resistant mutants. The lower the SI value, the stronger the ability to prevent drug resistance. The selection indexes of AP138 and A24 were 8 and 4, respectively, indicating that the ability of antimicrobial peptide A24 to prevent drug-resistant mutations is greater than that of the antibiotic ceftriaxone sodium.
[0046] Table 3 Antimicrobial peptides AP138 and A24 against Staphylococcus aureus MPC
[0047] Example 3 Kinetic curve of antimicrobial peptide A24 killing resistant Staphylococcus aureus
[0048] The logarithmic phase Staphylococcus aureus CVCC 546 and MRSA ATCC 43300 were diluted to 1 × 10 5 CFU / mL was set aside, and then different concentrations of AP138 or vancomycin or ceftriaxone sodium were added as controls, and an equal volume of sterile PBS was added as a blank control, and cultured at 37°C and 250 r / min. 100 μL was sampled every 1 h for gradient dilution colony counts, and a time-kill curve was drawn. The results are shown in Figure 1 and Figure 2As shown in the results, A24 has a killing effect on Staphylococcus aureus and is dose-dependent. A24 at 2 × MIC has a killing rate of 99.9% against multidrug-resistant bacteria MRSA ATCC43300 within 1 hour, and a killing rate of 99.9% against clinical isolate CVCC 546 within 2 hours. The killing rate of vancomycin or ceftiofur sodium at 2 × MIC is relatively slow, and the colony count drops to 2log10 CFU / mL at 6 hours. The results show that AP138 and A24 have significant rapid bactericidal advantages over antibiotics such as vancomycin or ceftiofur sodium, and A24 is more significant.
[0049] Example 4 Post-antibiotic effect (PAE) of antimicrobial peptide A24 on Staphylococcus aureus CVCC546
[0050] The logarithmic phase Staphylococcus aureus CVCC546 and MRSA ATCC43300 were diluted to 1×10 8 CFU / mL was set aside, and then different concentrations of antimicrobial peptide AP138 (1×, 2×, 4× MIC) or vancomycin (ceftiofur sodium) were added as controls, and the untreated group was used as a blank control, and incubated in a constant temperature incubator at 37°C for 2 h. Take 50 µL of the above sample and dilute it 1:1000 in fresh 50 mL MHB medium to remove the drug, and culture the bacteria at 37°C and 250 rpm. Take 50 µL of the sample at different time intervals for CFU counting until the bacterial culture becomes turbid. The calculation formula of PAE is as follows: PAE=TC
[0051] Where T is the time at which a 10-fold increase in CFU counts is observed immediately after drug removal and C is the corresponding time for the untreated control (OH et al, 2019).
[0052] The results are as follows Figure 3 and Figure 4 As shown in the figure, the post-antibiotic effects of antimicrobial peptide AP138 at different concentrations on multidrug-resistant Staphylococcus aureus strain MRSA ATCC43300 and clinical strain CVCC546 were longer than those of vancomycin, reaching a maximum of about 4 hours, and showed concentration dependence.
[0053] Example 5 Stability of antimicrobial peptide A24
[0054] First, a salt ion stability test was performed. The antimicrobial peptide A24 was incubated in 50 mM, 100 mM, 150 mM, 200 mM, and 300 mM NaCl solutions at 37°C for 2 h, and then the MIC experiment was performed. The specific steps were the same as those in Example 1.
[0055] After that, a thermal stability experiment was conducted. After the antimicrobial peptide A24 was incubated at 20°C, 40°C, 60°C, 80°C, and 100°C for 1 h, the MIC experiment was determined. The specific steps were the same as those in Example 1. The results showed that the antimicrobial peptide A24 maintained activity at a high salt concentration of 300 mM NaCl and maintained good antibacterial activity at 80°C. It has good high salt ion stability (Table 4-1) and high thermal stability (Table 4-2).
[0056] Table 4-1 Salt ion stability
[0057] Table 4-2 Thermal stability
[0058] Example 6 Stability of antimicrobial peptide A24 in mouse serum
[0059] 50 μL of A24 was placed in 25% serum and incubated at 37°C for 0 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 12 h. S. aureus The antibacterial activity of CVCC 546 was determined by MIC and the retention rate at different times was detected by HPLC. The results are shown in Table 5 and Figure 5 After incubation with serum, the antimicrobial peptides S. aureus The minimum inhibitory concentration of CVCC546 remained basically unchanged, and the retention rate of antimicrobial peptide A24 approached 100% after incubation for 12 h, indicating that antimicrobial peptide A24 has high stability in serum.
[0060] Table 5 Antimicrobial peptide A24 is stable in serum
[0061] Example 7 Effect of antimicrobial peptide A24 on the cell membrane integrity of Staphylococcus aureus CVCC 546
[0062] The 1:100 transferred Staphylococcus aureus was cultured to the logarithmic phase, resuspended and washed twice with PBS, and then prepared into 1 × 10 8 CFU / mL bacterial suspension, add antimicrobial peptide A24 to a final concentration of 2 × MIC, and add an equal volume of PBS solution as a negative control. After mixing the two, place them in a 37°C constant temperature incubator for 30 minutes, wash them with PBS 2-3 times, and then stain them with SYTO9 and PI (LIVE / DEAD BacLight Bacterial Viability Kit) for 15 minutes. Wash the guide piece with PBS and observe it under a fluorescence microscope. The results are as follows Figure 6As shown, untreated Staphylococcus aureus showed green fluorescence, while the bacteria treated with AP138 and A24 showed red or red and red light composite light, and the amount of bacteria was significantly reduced and the red light was more after A24 treatment, indicating that A24 can destroy the cell membrane of Staphylococcus aureus and cause rapid bacterial death.
[0063] Example 8 Entry of antimicrobial peptide A24 into cells and bactericidal effect on intracellular Staphylococcus aureus CVCC 546
[0064] The dilution of bovine uterine epithelial cells BEND or mouse macrophage RAW264.7 cells to maintain the best activity after subculture is 2 × 10 5 The cells / well were added to the confocal slide dish and placed in the cell culture incubator for culture. 1×, 2×, 4× MIC FITC-A24 and RAW246.7 cells (2 × 10 5 Cells / well) were incubated in a confocal dish at 37℃ 5% CO2 cell culture incubator for 24 h. Fluorescent dyes (membrane dye: WGA-conjugatedAlexa Fluor 555, nuclear dye: Hoechst 33342) with a final concentration of 5 μg / mL dye were added for staining for 15 min, washed 2-3 times with PBS, and then fixed with 4% paraformaldehyde. The results were observed under a confocal microscope (488 nm, 561 nm). Figure 7 As shown: the cell membrane is bound by WAG dye to emit red fluorescence, the cell nucleus is bound by Hoest dye to emit blue fluorescence, and a large amount of green fluorescence is distributed around the blue fluorescence and within the red fluorescence, indicating that FITC-labeled A24 can pass through the cell membrane and enter the cell to exhibit green fluorescence.
[0065] The bovine uterine epithelial cells BEND or mouse macrophage RAW264.7 were revived and passaged and adjusted to 2.5×10 5 cells / mL, inoculated into 12-well cell culture plates, 0.75 mL / well, cultured at 37°C, 5% CO2, saturated humidity for 24 h. Discard the culture medium and wash twice with PBS. S. aureus CVCC546 was cultured to mid-logarithmic phase, washed twice with PBS, and suspended in DMEM complete medium (without antibiotics) to a volume of 2.5 × 10 7CFU / mL, 0.75 mL / well was added to the BEND or RAW264.7 cell culture plate. After incubation for 30 min, an equal volume of DMEM complete medium dissolved lysostaphin (50 μg / mL) was added to remove non-phagocytic cells. After removing extracellular bacteria, 1 well of BEND or RAW264.7 cells was randomly selected as the control group, and 1 mL of cell lysis buffer was added to lyse the cells. The supernatant culture medium, PBS washing solution samples and cell lysate were diluted and plated, and the intracellular infection was recorded. Different concentrations (5 ×, 10 ×, 50 ×, 100 × MIC) of A24 and vancomycin solution (PBS as negative control) dissolved in an equal volume of DMEM complete medium were added to other wells and incubated for 24 h. The culture medium was discarded, PBS was washed twice, 1 mL of cell lysis buffer was added to lyse the cells, PBS was diluted and plated, and the cells were counted after incubation at 37°C for 18 h (Kamaruzzaman et al, 2016). The results are shown in Figure 8 As shown, antimicrobial peptide A24 has a good killing effect on intracellular bacteria, with an intracellular inhibition rate of 99.9%.
[0066] Example 9 Acute toxicity test of antimicrobial peptide A24 on mice
[0067] Eight mice (6-week-old SPF-grade ICR mice, purchased from Beijing Weitong Lihua Experimental Animal Co., Ltd.) were divided into two groups, with four mice in each group. The blank control group was injected with 0.9% saline, and the experimental group was intraperitoneally injected with 10 mg / kg A24 (200 μL each) for 7 consecutive days. Plasma and tissues were collected for routine blood tests, biochemical tests, and tissue section observations, respectively.
[0068] Blood routine, biochemical tests and tissue sections are shown in Tables 6, 7 and Fig. 9 The results showed that the above indicators had no abnormal changes compared with the blank control, indicating that the antimicrobial peptide A24 is safe for use in mice.
[0069] Table 6 Routine blood test
[0070] Table 7 Biochemical index detection
[0071] Example 10 Combination of antimicrobial peptide A24 and ceftiofur sodium
[0072] First, the combination index (FICI) was determined: the chessboard method was used to evaluate the synergistic effect of A24 and different antibiotics (ZHANGet al., 2021). The synergistic effect FICI was calculated as follows: FICI = FICA24 + FICantibiotics; FIC = MICc / MICa, where MICc is the MIC of the combination of peptide and antibiotic, and MICa is the MIC of the peptide / antibiotic alone. Three parallel experiments were performed in each group. Evaluation criteria: The efficacy of the combination therapy was defined as FICI ≤ 0.5, 0.5 <FICI≤1, 1<FICI≤4, FICI> 4, indicating synergy, addition, no difference and antagonism, respectively. The results are shown in Table 8. The FICI of antimicrobial peptide A24 with vancomycin, streptomycin sulfate, ceftiofur sodium and ampicillin are 0.5, 1, 0.5 and 1.015625, respectively. It has synergistic effects with ceftiofur sodium and vancomycin. Since ceftiofur sodium is a drug for the treatment of endometritis, antimicrobial peptide A24 and ceftiofur sodium were used in combination in the later stage.
[0073] Table 8 FICI Index
[0074] The inhibitory effect of A24 in combination with ceftiofur sodium on Staphylococcus aureus was further investigated by measuring the growth curve. Specific steps: Staphylococcus aureus in the logarithmic growth phase was diluted to 1 × 10 5 CFU / mL (ZHANG et al., 2021). Different concentrations of A24, ceftiofur sodium, and different concentrations of the mixture of the two were added to a 96-well microplate and reacted with an equal volume of bacteria. The growth curve was recorded using an automatic growth curve recorder. The results are shown in Fig.10 As shown in Figure 2, 1 / 2×MIC A24 and 1 / 8×MIC Cef alone could not completely inhibit its growth, but their combination could completely inhibit S. aureus The growth of CVCC546 again demonstrated that A24 could cooperate with ceftiofur sodium to inhibit the growth of Staphylococcus aureus.
[0075] Example 11 Determination of inflammatory factors in the treatment of endometritis in mice caused by Staphylococcus aureus by antimicrobial peptide A24 and its combination with ceftiofur sodium
[0076] The challenge and treatment scheme was consistent with that in Example 9. Blood was collected from the eyeballs and put into a 1.5 mL centrifuge tube 24 hours later to collect serum, and the inflammatory factor IL-6 was detected using an ELISA kit.
[0077] Inflammatory factors such as Fig.11As shown in the data, the level of proinflammatory factor IL-6 decreased after treatment with antimicrobial peptide A24 and its combination with ceftiofur sodium in a dose-dependent manner, and the combination group had the best effect, indicating that antimicrobial peptide A24 and the combination group can reduce the inflammatory level of endometritis.
[0078] Example 12 Determination of bacterial load in organs of antimicrobial peptide A24 and its combination with ceftiofuron in the treatment of endometritis caused by Staphylococcus aureus in mice
[0079] The challenge and treatment scheme was consistent with that in Example 9. Mice were killed 24 hours later, 100 mg of uterine tissue was weighed into a clean centrifuge tube containing 1 mL of PBS, and the tissue was homogenized. After smearing, the plate was incubated at 37°C overnight, and colonies were counted the next day. The bacterial load per unit mass of each tissue and organ in each treatment group was counted.
[0080] The results of bacterial load in mouse organs are shown in Fig.12 After treatment with different doses of antimicrobial peptide A24 and its combination with ceftiofur sodium, the bacterial load in the organs of mice was significantly reduced to a lower level compared with the control group. 10 mg / kg antimicrobial peptide A24 had a better effect, which was close to that of the combination group 5 mg / kg (A24+Cef), indicating that the combination of antimicrobial peptide A24 and ceftiofur sodium can inhibit Staphylococcus aureus in the body.
[0081] Example 13 Observation of pathological sections of antimicrobial peptide A24 and its combination with ceftiofuron against Staphylococcus aureus-induced endometritis in mice
[0082] After the mice were killed, another sample of the fixed weight tissue was weighed and placed in a 4% paraformaldehyde fixative, dehydrated at 4°C, and then subjected to the following procedures: (1) dehydration and embedding: sectioning (4 μM), baking (55°C); (2) xylene dewaxing: five sections, 10 min each; (3) hydration: Harris hematoxylin solution staining for 5-10 min; (4) eosin solution staining (95% ethanol solution) for 30 s; (5) neutral gum sealing and observation under an OLYMPUS BX43 microscope.
[0083] Histopathological sections Fig.13 As shown, after the antimicrobial peptide A24 and its combination with ceftiofur sodium were used to treat endometritis, the tissue structure returned to normal clear structure, there was no glandular atrophy and interstitial bleeding, and the inflammatory cells (lymphocytes, neutrophils) were significantly reduced to normal levels, indicating that the antimicrobial peptide A24 and its combination with ceftiofur sodium showed good in vivo therapeutic effect and can be used for the development of therapeutic drugs for animal endometritis in the later stage.
[0084] The present invention provides a drug combination for treating endometritis. Among them, the antimicrobial peptide A24 is a derivative peptide derived from the parent peptide AP138. AP138 and its derivative peptide A24 have efficient in vitro bactericidal activity against multidrug-resistant Staphylococcus, and show the characteristics of rapidity, long after-effect, low drug resistance and high safety. The bactericidal efficiency and antibiotic after-effect of the antimicrobial peptide A24 are significantly higher than those of vancomycin or ceftiofur sodium, and are better than those of the parent peptide AP138. Among them, A24 and ceftiofur sodium have a combined effect and have a good antibacterial effect in vivo and in vitro. AP138 and A24 are safe for use in mice, do not damage cells, tissues and organs, and have a better effect on endometritis infected with Staphylococcus aureus after being used in combination with low-concentration ceftiofur sodium. The combination of the drugs has a significant synergistic effect, which is more effective than a single drug in reducing or avoiding serious adverse reactions produced in the prevention and treatment of endometritis, and improving the prevention and treatment effect of endometritis.
[0085] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
[0086] References: 1. Eckert LO, Thwin SS, Hillier SL, Kiviat NB, Eschenbach DA. Theantimicrobial treatment of subacute endometritis: a proof of concept study. Am J Obstet Gynecol. 2004 Feb;190(2):305-13.
[0087] 2. Cheung GYC, Bae JS, Otto M. Pathogenicity and virulenceofStaphylococcus aureus. Virulence. 2021 Dec;12(1):547-569.
[0088] 3. Zasloff, Michael. Antimicrobial peptides of multicellularorganisms [J]. Nature, 2002, 415(6870):389-395.
[0089] 4. Mygind P H ,Fischer R L ,Schnorr K M ,et al .Plectasin is apeptide antibiotic with therapeutic potential from a saprophytic fungus[J].Nature (London) ,2005 ,437(7061):975-980 .
[0090] 5. Lociuro S, Neve S, Kjærulf S, Nordkild P.AP138, a secondgeneration plectasin, shows good bactericidal properties and long post-antibiotic effect Final Programme; European Congress of Clinical Microbiologyand Infectious Diseases April25–28\2015Copenhagen, Denmark.
[0091] 6. Groo AC, Matougui N, Umerska A, Saulnier P. Reverse micelle-lipidnanocapsules: a novel strategy for drug delivery of the plectasin derivateAP138 antimicrobial peptide. Int J Nanomedicine. 2018 Nov 15;13:7565-7574.doi: 10.2147 / IJN.S180040. PMID: 30532539; PMCID: PMC6241861.
[0092] 7 . Zhang Y ,Teng D ,Mao R ,Wang X ,Xi D ,Hu X ,Wang J .Highexpression of a plectasin-derived peptide NZ2114 in Pichia pastoris and itspharmacodynamics , postantibiotic and synergy against Staphylococcus aureus.Appl Microbiol Biotechnol .2014Jan;98(2):681-94。
Claims
1. Antimicrobial peptide A24, characterized in that: It comprises or consists of the following amino acid sequence: i) the amino acid sequence shown in SEQ ID NO: 2; or ii) An amino acid sequence obtained by connecting a tag to the N-terminus and / or C-terminus of i).
2. A nucleic acid molecule encoding the antimicrobial peptide according to claim 1.
3. A biological material containing the nucleic acid molecule according to claim 2, characterized in that: The biological material is recombinant DNA, expression cassette, transposon, plasmid vector, virus vector, engineering bacteria or transgenic cell line.
4. Use of the antimicrobial peptide according to claim 1 in the preparation of antimicrobial drugs or compositions; The bacteria are Gram-positive bacteria, preferably Staphylococcus aureus ( Staphylococcus aureus ).
5. Use of the antimicrobial peptide according to claim 1 in the preparation of a drug for preventing or treating endometritis; wherein: The pathogenic bacteria of endometritis include Staphylococcus aureus.
6. A drug for preventing or treating endometritis, characterized in that: The active ingredient of the drug is the antimicrobial peptide according to claim 1.
7. A drug combination for treating endometritis, characterized in that: The drug combination comprises the antimicrobial peptide according to claim 1 and ceftiofur sodium.
8. The pharmaceutical combination according to claim 7, characterized in that Antimicrobial peptides and ceftiofur sodium can be administered simultaneously or sequentially.
9. The pharmaceutical combination according to claim 7 or 8, characterized in that: The antimicrobial peptide A24 and ceftiofur sodium were administered by intraperitoneal injection.
